Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KLK11
REST API REST API
Homo sapiens
KLK11 is differentially expressed in 184 experiments: 134 organism parts: prostate, trachea, ... (132 more);, 88 disease states: normal, prostate carcinoma, ... (86 more);, 54 cell types 259 cell lines 15 compound treatments and 63 other conditions.
Synonyms PRSS20, TLSP
Orthologs Klk11 (Mus musculus)   KLK11 (Bos taurus)   Klk11 (Rattus norvegicus)   (Compare orthologs)
Gene Ontology Term peptidase activity, extracellular region, serine-type peptidase activity, proteolysis, serine-type endopeptidase activity
InterPro Term Peptidase_S1A, Peptidase_S1_S6
UniProt Accession Q8IXD7, Q9UBX7, Q0WXX5
Search EB-eye ENSG00000167757
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-24147, ... (17 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
SNU1
2
E-MTAB-37, E-GEOD-15460
BT474
2
E-MTAB-37, E-MEXP-440
HDMYZ
1
E-MTAB-37
HT1197
1
E-MTAB-37
C4II
1
E-MTAB-37
253 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-1121, E-GEOD-19397, E-GEOD-21668, E-GEOD-3920, ... (29 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
testis - germ cell
2
E-AFMX-5, E-TABM-145
squamous cell
1
E-GEOD-19397
leydig cell
1
E-MTAB-25
osteoblast
1
E-MEXP-1216
mononuclear
1
E-GEOD-26672
48 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-GEOD-20602, ... (39 experiments)

Factor Value U/D Experiments
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
head and neck squamous cell carcinoma
2
E-GEOD-6631, E-GEOD-2379
lung adenocarcinoma
2
E-MTAB-62, E-GEOD-2514
prostate carcinoma
1
2
E-GEOD-7307, E-GEOD-96, E-MTAB-62
Mantle cell lymphoma
1
E-GEOD-18736
dermatomyositis
1
E-GEOD-5370
82 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-3284, E-GEOD-5741, E-GEOD-412, E-GEOD-6462, ... (8 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-5741, E-GEOD-412, E-GEOD-4668
hydrogen peroxide
1
E-GEOD-5339
17beta-estradiol
4
1
E-GEOD-4668
bacterial endotoxin
1
1
E-GEOD-3284
propofol
1
E-GEOD-4386
LDL
1
E-GEOD-5741
9 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-108

Genotype
studied in E-MEXP-1996, E-GEOD-22056, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-20540, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-GEOD-1926, E-TABM-666, E-GEOD-19330, E-GEOD-19519, ... (22 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-1643

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-6532

Processing time: 0.472 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM